{"transactions":[{"id":713056,"issuer":{"id":6537,"kind":"organization","name":"KAZIA THERAPEUTICS LTD"},"owners":[{"id":31508,"kind":"person","name":"Coffey Steven R. S.","position":1,"cik":"0002121676","reported_name":"Coffey Steven R. S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-07-08T20:59:30.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029."}],"balance_after":100000,"derivative":{"exercise_price":9.1,"underlying":"ADSs","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-26-076431","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1075880/000121390026076431/ownership.xml","form_type":"4"}}]}